<DOC>
	<DOCNO>NCT01275508</DOCNO>
	<brief_summary>The scientific objective project evaluate topical administration Fluoresceinisothiocyanate ( FITC ) -Adalimumab endomicroscopic examination gut Crohn 's disease ( CD ) patient show acceptable safety profile . Another objective explore whether use FITC-Adalimumab predictive biomarker might reliably predict patient response Adalimumab therapy hence enable optimized utilization treatment option .</brief_summary>
	<brief_title>Safety Tolerability FITC-Adalimumab Administration During Confocal Laser Endomicroscopy Gut</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Trial subject must meet follow inclusion criterion : Male female subject 18 70 year age capable give informed consent without restriction Endoscopically histologically confirm diagnosis Crohn 's disease ( CD ) Manifestation CD colon and/or terminal ileum Currently active CD CDAI score &gt; 150 Clinically inadequate response CD systemic glucocorticoid and/or immunosuppressant ( azathioprine , 6mercaptopurine , methotrexate ) glucocorticoiddependent CD contraindication glucocorticoid Indication treatment Adalimumab Indication intestinal confocal laser endomicroscopy prior institution adalimumab therapy Subject mentally capable understanding nature purpose/conduct clinical trial follow study staff 's instruction Subject give write informed consent inform investigator Female subject additionally must meet least one follow criterion : Must menopausal ( least 12 month ' natural amenorrhea 6 month ' amenorrhea serum FSH &gt; 40 mU/mL ) Must undergone bilateral oophorectomy hysterectomy Must regular , correct , reliable user contraceptive method failure rate &lt; 1 % per year ( oral contraceptive , implant , depot shot , intrauterine device , hormone coil ) Must vasectomize partner Subjects must meet follow exclusion criterion : Impaired blood clotting ( prothrombin rate &lt; 50 % and/or PTT &gt; 55 sec and/or platelet count &lt; 50,000/Î¼L ) Pregnancy lactation Contraindications treatment adalimumab : Moderate severe heart failure ( NYHA Class III/IV ) Active tuberculosis Severe acute infection , e.g . sepsis Opportunistic infection include invasive fungal infection Known hypersensitivity ingredient study product drug similar chemical structure Treatment betareceptor block agent ( alter symptom case possible anaphylactic reaction IV fluorescein ) Any condition medical treatment , investigator 's judgment , compatible participation trial Individuals relationship dependence employ sponsor investigator Planned prolonged stay outside region study site , prevent subject return schedule visit Participation clinical trial administration investigational drug within last four week prior screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Subjects active Crohn 's disease</keyword>
	<keyword>Safety tolerability FITC-Adalimumab</keyword>
	<keyword>Intestinal topical application</keyword>
</DOC>